The Rationale for Current Pharmacotherapy of Covid19

Severe acute respiratory syndrome (SARS-CoV), Middle East respiratory syndrome (MERS) and SARS-CoV-2 are related to the coronaviridae family. The worldwide pandemic of the new coronavirus disease 2019 (COVID -19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) broke out in Wuhan province of China, in December 2019, and spread rapidly throughout the world. More than 6 million cases and 370,000 deaths had been reported by 31 May 2020 in more than 200 countries. No data are available from any clinical trials supporting a proposed prophylactic therapy. More than 300 active clinical trials are currently underway. Many drugs have been studied against COVID-19, but there is no actual evidence from any randomized clinical trials with a potential therapy that can improve outcomes of a patient diagnosed with COVID-19. In some cases, many of the investigated drugs cause side effects, e.g. chloroquine, ribavirin. Besides its beneficial effects such as reducing disease progression and decreasing symptom duration, chloroquine can cause cardiac side effects. Ribavirin, on the other hand, is recognized as a teratogen and considered unsafe in pregnancy. No special effective antiviral therapy against COVID-19 is currently available. Although the course of the disease is mild and moderate in the majority of the COVID-19 patients, more than 5%-7% of the patients' life being under severely susceptible threats requires more effective medicinal products, urgently

PDF

___

1. Schwartz D, Graham A. Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: Lessons from SARS, MERS, and other human coronavirus infections. Viruses; 2020; doi: 10.3390/v12020194.

2. Payne S. Family Coronaviridae. Viruses 2017; 149-158.

3. Kwok K, Tang A, Wei V, Park W, Yeoh E, Riley, S. Epidemic Models of Contact Tracing: Systematic Review of Transmission Studies of Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome. Comput Struct Biotechnol J; 2019; 17: 186-194.

4. Peeri, N, Shrestha N, Rahman M, Zaki R, Tan Z, Bibi S, Baghbanzadeh M, Aghamohammadi N, Zhang W, Haque U. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?. International journal of epidemiology; 2020; doi: 10.1093/ije/dyaa033.

5. Saber-Ayad M, Saleh M, Abu-Gharbieh E. The rationale for potential pharmacotherapy of COVID-19, Pharmaceuticals; 2020; 13: 96.

6. Zhu N, Zhang D, WangW, Li X, Yang B, Song J, Zhao X, Huang B.China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, N Engl J Med; 2020, 382: 727-733.

7. Sanders J, Monogue M, Jodlowski T, Cutrell J.Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) A Review free access. JAMA; 2020; 323: 1824-1836.

8. Turner D, Huang Y, Martín-de-Carpi J, et al. COVID-19 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto group of ESPGHAN. J Pediatr Gastroenterol Nutr; 2020; 70(6):727- 733.

9. Poggiali E, Ramos P, Bastoni D, Vercelli A, Magnacavallo A. Abdominal Pain: A Real Challenge in Novel COVID-19 Infection. European Journal of Case Reports in Internal Medicine; 2020; doi:10.12890/2020_001632.

10. Garami A. Rapid response: Preventing a covid-19 pandemic - Is there a magic bullet to save COVID-19 patients? We can give it a try!. British Medical Journal; 2020. doi.org/10.1136/bmj.m810.

11. Huang C, Wang Y, Li X, Ren L, Zhao J, et.al. Clinical features of patients infected with 2019 novel coronavirus inWuhan, China. Lancet; 2020; 395: 497-506.

12. Uyeki T, Bernstein H, Bradley J, Englund J, File T, et al. Clinical practice guidelines by the infectious diseases society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa. Clinical Infectious Disesases; 2019; 6: 895-902.

13. Guo Y, Cao Q, Hong Z, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Military Medical Research; 2020; doi:10.1186/s40779- 020-00240-0

14. Zhou D, Dai SM, Tong Q. COVID-19.a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother; 2020;75(7):1667-1670.

15. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents; 2020; 55(4):105932.

16. Lim HS, ImJS, Cho JY, et al. Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother 2009; 53: 1468-1475.

17. Chu C, Cheng V, Hung I, et al, HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59: 252-256.

18. Alhazzani W, Møller M, Arabi Y, et al. Surviving Sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Medicine 2020; 46: 854-858.

19. Hayden F, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis; 2019; 32: 176-186.

20. Siegel D, Hui H, Doerffler E, et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine Cnucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem; 2017; 60: 1648-1661.

21. Sheahan T, Sims A, Leist S, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun; 2020; doi:10.1038/s41467-019- 13940-6

22. Schrezenmeie E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nature Reviews Rheumatology 2020; 16: 155- 166.

23. Vincent M, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J; 2005; doi:10.1186/1743-422X-2-69

24. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends; 2020; 14: 72-73.

25. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Main point: Hydroxychloroquine was found to be more potent than chloroquine at inhibiting SARS-CoV-2. Clin Infect Di; 2020, doi:10.1093/cid/ciaa237

26. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience Trends 2020; 16: 14: 72-73.

27. Chu C, Cheng V, Hung I, et al. HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59: 252-256.

28. Oldfield V, Plosker GL. Lopinavir/Ritonavir. Drugs [Internet]. 2006; 66(9):1275-99.

29. Chan K, Lai S, Chu C, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 2003; 9: 399-406.

30. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020; 7: 382: 1787-1799.

31. Booth C, Matukas L, Tomlinson G, Rachlis A, Rose D, Dwosh H, et al. Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area. JAMA 2003; 289: 2801-2809.

32. Booth C, Matukas L, Tomlinson G, Rachlis A, Rose D, Dwosh H, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. JAMA 2003; 289: 2801-2809.

33. Chu C, Cheng V, Hung I, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59: 252-256.

34. Al-Tawfiq J, Momattin H, Dib J, Memish Z. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis; 2014; 20: 42-46.

35. Stockman L, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med; 2006, doi: 10.1371/journal.pmed.0030343.

36. Saber-Ayad M, Saleh M, Abu-Gharbieh E. The Rationale for Potential Pharmacotherapy of COVID-19. Pharmaceuticals 2020.

37. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad-spectrum inhibitor of viral RNA polymerase. Proceedings of the Japan Academy Series B 2017; 93: 449-463.

38. Mentré F, Taburet AM, Guedj J, et al. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis 2015; 15: 150-151.

39. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14: 58-60.

40. Chinello P, Petrosillo N, Pittalis S, Biava G, Ippolito G, Nicastri E; QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient. PLoS Negl Trop Dis; 2017; doi:10.1371/journal.pntd.0006034

41. Kumagai Y, Murakawa Y, Hasunuma T, et al. Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults. Int J Clin Pharmacol Ther; 2015; 53: 866-874.

42. Chow E, Doyle J, Uyeki T. Influenza virusrelated critical illness: prevention, diagnosis, treatment. Crit Care; 2019; doi:10.1186/s13054-019-2491-9

43. Siegel D, Hui H, Doerffler E, et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine Cnucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem; 2017; 60: 1648-1661.

44. Yavui S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci; 2020; 50: 611- 619.

45. Holshue M, DeBolt C, Lindquist S, Lofy K, Wiesman J et al. First Case of 2019 Novel Coronavirus in the United States. New England Journal of Medicine 2020; 382: 929- 936.

46. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research 2020; 30: 269-271.

47. Lescure F-X, Bouadma L, Nguyen D, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis 2020; 20: 697-706.

48. Poschet J, Perkett E, Timmins G, Deretic V. Azithromycin and ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells. bioRxiv. 2020; doi:10.1101/2020.03.29.008631

49. Molin J, Delaugerre C, Goff J, Mela-Limaa B, Ponscarme D, Goldwirte L, de Castroa N. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Médecine et Maladies Infectieuses; 2020; doi:10.1016/j.medmal.2020.03.006

50. Gautret P, Lagier J-C, Parola P.Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial. Int J Antimicrob Agents; 2020; doi:10.1016/j.ijantimicag.2020.105949

51. Lane J, Weaver J, Kostka K, et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid widespread use for COVID-19: a multinational, network cohort and self-controlled case series study. medRxiv; 2020; doi: 10.1101/2020.04.08.20054551

52. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med; 2020, 2020;46(5):846-848.

53. Commission TCNH. Chinese Clinical Guidance For COVID-19 Pneumonia Diagnosis and Treatment. Microbiol Rev 2020.

54. Liu A. Roche launches clinical trial of COVID-19 pneumonia hopeful Actemra after backing from China. J Med Chem; 2020; 209- 218.

55. Mahamid M, Paz K, Reuven M, Safadi R. Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports. Int J Gen Med; 2011; 4: 657-660.

56. Xu X, Han M, Li T.Effective Treatment of Severe COVID-19 Patients With Tocilizumab. Proc Natl Acad Sci U S A; 2020; 117: 10970- 10975.

57. Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D. Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti- TNFTargeted Biologics. Mediators Inflamm; 2017, doi:10.1155/2017/8909834

58. Kadam R, Wilson I. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci U S A; 2017; 114: 206-214.

59. Boriskin Y, Leneva I, Pecheur E-I, Polyak S. Arbidol: A Broad-Spectrum Antiviral Compound that BlocksViral Fusion. Curr Med Chem; 2008; 15: 997-1005.

60. Khamitov R, Loginova S, Shchukina V, Borisevich S, Maksimov V, Shuster A. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures [in Russian]. Vopr Virusol; 2008; 53: 9-13.

61. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost; 2020; 18: 844-847.

62. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost; 2020; doi.org/10.1111/jth.14817

63. Mycroft-West C, Su D, Elli S, et al. The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 receptor binding domain undergoes conformational c h a n g e upon h e p a r i n bi n d ing. bi o Rxi v; 2020; 02.29.971093.

64. Shi C, Wang C, Wang H, Yang C, Cai FEI, Zeng F et al. The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective clinical study. medRxiv; 2020: 2020.03.28.20046144.

65. Villar J, Belda J, Anon JM, et al. Evaluating the efficacy of dexamethasone in the treatment of patients with persistent acute respiratory distress syndrome: study protocol for a randomized controlled trial. Trials; 2016; 17: 342.

66. Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol; 2020; doi:10.1016/j.clim.2020.108393

67. Lamontagne F, Rochwerg B, Lytvyn L, et al. Corticosteroid therapy for sepsis: a clinical practice guideline. BMJ; 2018; doi:10.1136/bmj.k3284

68. WHO. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected.

69. Wu R, Wang L, Kuo HD, et al. An Update on Current Therapeutic Drugs Treating COVID19 [published online ahead of print, 2020 May 11]. Curr Pharmacol Rep; 2020; 1-15.

70. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARSCoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study Lancet Respir Med; 2020; 8(5): 475-481.

71. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy; 2020; 75(7):1730-1741.

72. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med; 2020, doi:10.1016/S2213- 2600(20)30116-8

73. Gurwitz D. Angiotensin receptor blockers as tentative SARSCoV-2 therapeutics. Drug Dev Res; 2020; doi:10.1002/ddr.21656

74. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med; 2005; 11: 875-879.

75. Kuba K, Imai Y, Ohto-Nakanishi T, Penninger JM. Trilogy of ACE2: A peptidase in the renin–angiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacol Ther [Internet]; 2010; 128: 119-128.

76. Salvi R, Patankar P. Emerging pharmacotherapies for COVID-19. Biomed Pharmacother; 2020; doi:10.1016/j.biopha.2020.110267

77. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res; 2020; 116: 1097-1100.